[ad_1]
With the beginning of the eighth month of the worst pandemic in a hundred years, these preliminary results will encourage companies to ask regulators for permission to use the vaccine immediately if further research shows that it is safe.
The findings are based on an interim analysis of 94 subjects with COVID-19. Testing of the vaccine will continue until the number reaches 164. If the preliminary data is confirmed and the safety information that Pfizer expects to receive in about a week is also encouraging, the world may have a new essential tool to manage a pandemic that has been charged more than 1 year. , 2 millions. lives.
“This is the best news for the world, the United States, and public health,” said William Gruber, senior vice president of clinical research and vaccine development at Pfizer. The results exceeded even the highest expectations, he admitted.
The effectiveness of the first vaccines was expected to be between 60 and 70%, “more than 90%. it’s an incredible result, ”said Ugur Sahin, CEO of BioNTech.
Filling
[ad_2]
